SCHEMBL2318142

SCHEMBL2318142

Nc1ccc2c(=O)n(Cc3ccc(Cl)cc3)cnc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.59
HDAC6 Q9UBN7 3/20 0.57
SCD O00767 2/20 0.52
TNF P01375 1/20 0.49
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GRK2 P25098 1/20 0.47
GRK1 Q15835 1/20 0.47
KCNH2 Q12809 1/20 0.47
MAPK1 P28482 2/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
HTT P42858 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC3 O15379 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2318321 0.89 SCD (0.61) PDE5AHDAC6SCDTNFTP53
SCHEMBL2312640 0.88 SCD (0.63) PDE5AHDAC6SCDTNFSMN1; SMN2
SCHEMBL2314971 0.87 MMP13 (0.56) PDE5AHDAC6SCDTNFSMN1; SMN2
SCHEMBL2315109 0.86 PDE5A (0.50) PDE5AHDAC6SCDTNFGRK2
SCHEMBL14478795 0.81 PDE5A (0.65) PDE5AHDAC6SCDSMN1; SMN2HPGD
SCHEMBL5532025 0.80 RAB9A (0.65) SCDSMN1; SMN2MAPK1CYP11B1CYP11B2
SCHEMBL2317452 0.80 MAPT (0.71) PDE5AHDAC6SMN1; SMN2ALDH1A1MAPK1
SCHEMBL2315711 0.78 SCD (0.63) SCDTNFSMN1; SMN2GRK2MAPK1
SCHEMBL2315631 0.78 SCD (0.58) PDE5ASCDSMN1; SMN2KDM4EALDH1A1
SCHEMBL2312920 0.77 MMP13 (0.60) HDAC6SCDTNFSMN1; SMN2GRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350029-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS Gilead Sciences, Inc. (US) 2011-08-03 EP disclosed
WO-2010056230-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS CV THERAPEUTICS, INC. (US) 2010-05-20 WO disclosed
US-20090105283-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD PALO ALTO, INC. 2009-04-23 US disclosed
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD PALO ALTO, INC. 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS SCD, SCD5, ECHS1 PDE5A 3459/4885HDAC6 1737/4885SCD 1/4885
US-20090105283-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS SCD, SCD5, ECHS1 PDE5A 3459/4885HDAC6 1737/4885SCD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.